Skip to content
A.T. Still University
Prospective Students
Current Students

iConnect News
ATSU Headlines
Arizona Campus Missouri Campus ASDOH ASHS KCOM SOMA Awards Community Health Centers Graduations Grants

Student Headlines AZ Student Affairs MO Student Affairs ATSU Portal Login

Alumni Headlines Classnotes In Memoriam Continuing Education

Faculty & Staff
Faculty/Staff Headlines Research & Publications ATSU Portal Login

iConnect Newsletter Grants & You Newsletter Athletic Training Alumni Newsletter Still Partner Newsletter Still- Well Being Newsletter Healthy Investments ATSU Research
A.T. Still Library Newsletter
Still Magazine
Current Issue
Past Issues
Donor Recognition
Hot Sheet
In Memoriam
The Last Word
Web Exclusives
President’s Desk
Research News
Spark magazine 2017-18
Spark magazine 2019-20
Supplement 2019
Fall 2019
Spring 2019
Summer 2019
Winter 2019
Supplement 2018
Fall 2018
Summer 2018
Spring 2018
Winter 2018
Supplement 2017
Fall 2017
Summer 2017
Spring 2017
Winter 2017
Museum of Osteopathic Medicine

iConnect News

ATSU-KCOM awarded National Institutes of Health R15 grant

September 26, 2018
Posted In: KCOM, Missouri Campus, University Headlines

The National Institutes of Health (NIH) announced its full funding of an A.T. Still University-Kirksville College of Osteopathic Medicine (ATSU-KCOM) three-year study through its Academic Research Enhancement Award (R15 grant). The study’s principal investigator, Yohei Norimatsu, PhD, assistant professor, physiology, ATSU-KCOM, submitted his award application and study, “Atomic-Scale Refinement of CFTR and TAAR1 Molecular Models for the Study of Drug Binding,” in October 2017; the NIH Notice of Award was received August 2018 totaling $382,343.

The three-year study, which will occur Sept. 1, 2018, through Aug. 31, 2021, will support Dr. Norimatsu’s research to improve design and discovery of pharmacological therapies for cystic fibrosis (CF), secretory diarrhea, schizophrenia, and drug addiction through atomic-level modeling of protein drug targets.

“The funding allows me to investigate how protein structures and dynamics of CFTR and TAAR1 relate to their functions, and accelerates our research toward the long-term goal of in silico drug screening and structure-based drug design,” said Dr. Norimatsu. “I hope this study will lead to collaborations with other investigators within ATSU and beyond. What is exciting to me is that extra funding resources make it possible to have more students in my lab to experience biomedical research.”

Cystic fibrosis transmembrane conductance regulator (CFTR) is a drug target for CF, the most common lethal genetic disease in the U.S., and secretory diarrhea, which is one of the leading causes of death among children globally. Trace amine-associated receptor 1 (TAAR1) is a promising drug target for schizophrenia, a devastating psychiatric illness that affects approximately 1 percent of the U.S. population, and drug addiction, which is causing at least 196 drug overdose deaths every day in the U.S.

Dr. Norimatsu is the second ATSU researcher to earn an NIH R15 research grant within the past year, which is a first in ATSU history. In September 2017, Tara McIsaac, PT, PhD, associate professor of physical therapy at ATSU’s Arizona School of Health Sciences earned NIH R15 grant funding for her research on “Multi-limb Control in Parkinson’s Disease: Implicit and Explicit Control of Attention.”

Dr. Norimatsu will be assisted by Oliver Beckstein, PhD, Arizona State University, co-developer of dynamic importance sampling techniques used within the study.

One response to “ATSU-KCOM awarded National Institutes of Health R15 grant”

  1. Lisa Archer says:

    Congratulations Dr. Norimatsu!!!!!

« »